Komori
Share Issuance and Disposal9267Genky DrugStores Co.,Ltd.Retail

Notice Regarding the Finalization of the Terms of Stock Options (Share Acquisition Rights)

The issuance terms for the stock options approved on 10 September 2026 have been finalized. A total of 1,000 stock acquisition rights will be allotted at no charge to 211 in-house directors and directors and employees of subsidiaries.

Worth reading
42Recurring
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
100000
Shares (1,000 stock acquisition rights, 100 shares per right)
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issuance of stock acquisition rights as stock options

発行・処分する株式数

100,000 shares (1,000 stock acquisition rights, 100 shares per right)

Intended allottee
Category The Company's in-house directors (excluding directors who are Audit and Supervisory Committee members), and directors and employees of the Company's subsidiaries / Number of Employees 211 people / Number allocated 1,000 rights
No cash payment required (stock acquisition rights)
Total issue value

No cash payment required (stock acquisition rights)

Terms of the stock acquisition rights
Exercise price
¥3,812 per share. Adjustment provisions and adjustment floor: Not disclosed
Number of Stock Acquisition Rights
Total issued: 1,000 rights. Unexercised balance: Not disclosed
Categories and Number of Persons Covered
The Company's in-house directors (excluding directors who are Audit and Supervisory Committee members), and directors and employees of the Company's subsidiaries: 211 people, 1,000 rights
Procedures under the Corporate Code of Conduct
Approved at the ordinary general meeting of shareholders on 10 September 2026
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of stock acquisition rights as stock options
Number of shares to be issued or disposed of100,000 shares (1,000 stock acquisition rights, 100 shares per right)
Issue price and disposal priceNo cash payment required (stock acquisition rights)
Total issue valueNo cash payment required (stock acquisition rights)
Intended allotteeCategory The Company's in-house directors (excluding directors who are Audit and Supervisory Committee members), and directors and employees of the Company's subsidiaries / Number of Employees 211 people / Number allocated 1,000 rights
Exercise price¥3,812 per share. Adjustment provisions and adjustment floor: Not disclosed
Number of Stock Acquisition RightsTotal issued: 1,000 rights. Unexercised balance: Not disclosed
Categories and Number of Persons CoveredThe Company's in-house directors (excluding directors who are Audit and Supervisory Committee members), and directors and employees of the Company's subsidiaries: 211 people, 1,000 rights
Procedures under the Corporate Code of ConductApproved at the ordinary general meeting of shareholders on 10 September 2026
Items this document does not state (19)
Amount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The issuance terms for the stock acquisition rights as stock options have been finalized.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Finalization of the Terms of Stock Options (Share Acquisition Rights) | Genky DrugStores Co.,Ltd. (9267) timely disclosure | Komori